Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Neoadjuvant nivolumab or nivolumab plus ipilimumab in early-stage triple-negative breast cancer: a phase 2 adaptive trial ; volume:30 ; number:11 ; day:16 ; month:9 ; year:2024 ; pages:3223-3235 ; date:11.2024
Nature medicine ; 30, Heft 11 (16.9.2024), 3223-3235, 11.2024
- Creator
-
Nederlof, Iris
Isaeva, Olga I.
Graaf, Manon de
Gielen, Robbert C. A. M.
Bakker, Noor A. M.
Rolfes, Adrianne L.
Garner, Hannah
Boeckx, Bram
Traets, Joleen J. H.
Mandjes, Ingrid A. M.
Maaker, Michiel de
Brussel, Thomas van
Chelushkin, Maksim
Champanhet, Elisa
Lopez-Yurda, Marta
Vijver, Koen van de
Berg, José G. van den
Hofland, Ingrid
Klioueva, Natasja
Mann, Ritse M.
Loo, Claudette E.
Duijnhoven, Frederieke H. van
Skinner, Victoria
Luykx, Sylvia
Kerver, Emile
Kalashnikova, Ekaterina
Dongen, Marloes G. J. van
Sonke, Gabe S.
Linn, Sabine C.
Blank, Christian U.
Visser, Karin E. de
Salgado, Roberto
Wessels, Lodewyk F. A.
Drukker, Caroline A.
Schumacher, Ton N.
Horlings, Hugo M.
Lambrechts, Diether
Kok, Marleen
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1038/s41591-024-03249-3
- URN
-
urn:nbn:de:101:1-2502040941451.862948456107
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:24 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Nederlof, Iris
- Isaeva, Olga I.
- Graaf, Manon de
- Gielen, Robbert C. A. M.
- Bakker, Noor A. M.
- Rolfes, Adrianne L.
- Garner, Hannah
- Boeckx, Bram
- Traets, Joleen J. H.
- Mandjes, Ingrid A. M.
- Maaker, Michiel de
- Brussel, Thomas van
- Chelushkin, Maksim
- Champanhet, Elisa
- Lopez-Yurda, Marta
- Vijver, Koen van de
- Berg, José G. van den
- Hofland, Ingrid
- Klioueva, Natasja
- Mann, Ritse M.
- Loo, Claudette E.
- Duijnhoven, Frederieke H. van
- Skinner, Victoria
- Luykx, Sylvia
- Kerver, Emile
- Kalashnikova, Ekaterina
- Dongen, Marloes G. J. van
- Sonke, Gabe S.
- Linn, Sabine C.
- Blank, Christian U.
- Visser, Karin E. de
- Salgado, Roberto
- Wessels, Lodewyk F. A.
- Drukker, Caroline A.
- Schumacher, Ton N.
- Horlings, Hugo M.
- Lambrechts, Diether
- Kok, Marleen
- SpringerLink (Online service)
Other Objects (12)
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Neoadjuvant relatlimab and nivolumab in resectable melanoma
PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Neoadjuvant relatlimab and nivolumab in resectable melanoma
PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease
Severe hemophagocytic lymphohistiocytosis in a melanoma patient treated with ipilimumab + nivolumab
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms
Nivolumab plus Ipilimumab : Erstlinientherapie beim fortgeschrittenen Nierenzellkarzinom
Nivolumab plus Ipilimumab, Nivolumab adjuvant : Diskussion zur Therapieentscheidung bei BRAF-mutierten Melanom Patienten
Nivolumab adjuvant, Nivolumab plus Ipilimumab : Meilensteine in der Behandlung des malignen Melanoms : Update 2021
Severe Gastritis after Administration of Nivolumab and Ipilimumab
Delayed onset of neurosarcoidosis after concurrent ipilimumab/nivolumab therapy
Retinal toxicity after initial administration of nivolumab and ipilimumab
Agnostic evaluation of ipilimumab and nivolumab association: a metanalysis
Neoadjuvant relatlimab and nivolumab in resectable melanoma
PRIME-HCC: phase Ib study of neoadjuvant ipilimumab and nivolumab prior to liver resection for hepatocellular carcinoma
Neoadjuvant immunotherapy with combined ipilimumab and nivolumab in patients with melanoma with primary or in transit disease